Hologic, Inc. (NASDAQ:HOLX) had its price target raised by Stifel Nicolaus from $45.00 to $48.00 in a research note issued to investors on Thursday, May 11th, MarketBeat reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus’ price target points to a potential upside of 8.30% from the company’s current price.
A number of other research firms also recently issued reports on HOLX. Canaccord Genuity restated a “buy” rating and set a $53.00 price objective on shares of Hologic in a report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a report on Tuesday, April 4th. Needham & Company LLC raised their price objective on shares of Hologic from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, April 4th. Leerink Swann reiterated an “outperform” rating and set a $52.00 target price on shares of Hologic in a research report on Thursday, March 30th. Finally, Barclays PLC set a $50.00 price objective on shares of Hologic and gave the company a “buy” rating in a research report on Wednesday, April 5th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Hologic currently has an average rating of “Buy” and a consensus target price of $47.54.
Hologic (NASDAQ HOLX) opened at 44.32 on Thursday. The stock’s 50 day moving average is $44.25 and its 200 day moving average is $41.75. The firm has a market capitalization of $12.41 billion, a price-to-earnings ratio of 15.89 and a beta of 0.94. Hologic has a 1-year low of $32.81 and a 1-year high of $46.05.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The business had revenue of $715.40 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter last year, the company posted $0.47 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. Analysts predict that Hologic will post $2.01 EPS for the current fiscal year.
In other Hologic news, Director Elaine Ullian sold 9,104 shares of Hologic stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $42.40, for a total transaction of $386,009.60. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at $1,009,544. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 10,757 shares of Hologic stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $42.45, for a total transaction of $456,634.65. Following the transaction, the director now directly owns 24,596 shares in the company, valued at $1,044,100.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 118,252 shares of company stock valued at $5,158,821. 0.79% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. increased its position in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the period. American Century Companies Inc. increased its position in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Norges Bank purchased a new position in shares of Hologic during the fourth quarter valued at approximately $83,300,000. Alyeska Investment Group L.P. increased its position in shares of Hologic by 1,631.9% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,875,534 shares of the medical equipment provider’s stock valued at $75,246,000 after buying an additional 1,767,240 shares during the last quarter. Finally, Investec Asset Management LTD purchased a new position in shares of Hologic during the fourth quarter valued at approximately $68,258,000. 94.50% of the stock is currently owned by hedge funds and other institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.